Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;50(5):506-10.

Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment

Carlos H de M Souza  1 , Evandro Toledo-Piza, Renee Amorin, Andrigo Barboza, Karen M Tobias
Affiliations

Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment

Carlos H de M Souza et al. Can Vet J. 2009 May.

Abstract
in English, French

Canine inflammatory mammary carcinoma (IMC) is a rare, locally aggressive, highly metastatic tumor that is poorly responsive to treatment. The purposes of this study were to retrospectively evaluate the history, signalment, and clinical signs of dogs with IMC; compare the outcome of affected dogs treated with traditional chemotherapy with those treated with piroxicam; evaluate Cox-2 expression of IMC cells; and correlate Cox-2 expression with outcome based on treatment. Strong cyclooxygenase-2 expression was present in all tumors. Improvement in clinical condition and disease stability was achieved in all dogs treated with piroxicam, with mean and median progression-free survival of 171 and 183 days, respectively. Median survival time of 3 dogs treated with doxorubicin-based protocols was 7 days, which was significantly less than that of dogs treated with piroxicam (median, 185 days). In conclusion, piroxicam should be considered as a single agent for the treatment of dogs with inflammatory mammary carcinoma.

Carcinome mammaire inflammatoire chez 12 chiens : caractéristiques cliniques, expression de la cyclo-oxygénase-2 et réponse au traitement au piroxicam. Le carcinome mammaire inflammatoire (CMI) canin est une tumeur rare, localement agressive et fortement métastatique qui répond mal au traitement. Les buts de cette étude étaient d’évaluer rétrospectivement l’anamnèse, le signalement et les signes cliniques des chiens atteint d’un CMI; de comparer les résultats des chiens affectés traités par la chimiothérapie traditionnelle avec ceux des chiens traités au piroxicam; d’évaluer l’expression de la Cox-2 des cellules du CMI; et d’établir un lien entre l’expression de la Cox-2 avec le résultat basé sur le traitement. Une forte expression de la cyclo-oxygénase-2 était présente dans toutes les tumeurs. L’amélioration de la condition clinique et de la stabilité de la maladie a été réalisée chez tous les chiens traités au piroxicam, avec une survie moyenne et médiane sans progression de 171 et de 183 jours, respectivement. La durée de survie médiane des 3 chiens traités avec des protocoles basés à la doxorubicine était de 7 jours, ce qui était une durée considérablement inférieure à celle des chiens traités au piroxicam (médiane de 185 jours). En conclusion, le piroxicam devrait être considéré comme un agent individuel pour le traitement des chiens atteints du carcinome mammaire inflammatoire.

(Traduit par Isabelle Vallières)

PubMed Disclaimer

Figures

Figure 1
Figure 1
Inflammatory mammary carcinoma affecting the 4th and 5th left mammary glands. Note the erythematous discoloration, and ulceration (circle). The tumor invades the medial aspect of the left thigh (arrow).
Figure 2
Figure 2
Hematoxylin and eosin (20×). Anaplastic carcinoma displaying dermal lymphatic invasion (arrow).
Figure 3
Figure 3
Numerous neoplastic cells are present inside dermal lymphatics (arrow). Steptavidin-biotin peroxidase stained positively for COX-2 (40×).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: Rev Clin Oncol. 1992;10:1014–1024. - PubMed
    1. Perez-Alenza MD, Tabañera H, Pena L. Inflammatory mammary carcinoma in dogs: 33 cases (1995–1999) J Am Vet Med Assoc. 2001;219:1110–1114. - PubMed
    1. Susaneck SJ, Allen TA, Hoopes J, Withrow SJ, Macy DW. Inflammatory mammary carcinoma in the dog. J Am Anim Hosp Assoc. 1983;19:971–976.
    1. Pena L, Perez-Alenza D, Rodriguez-Bertos A, Nieto A. Canine inflammatory mammary carcinoma: Histopathology, immunohistochemistry, and clinical implications of 21 cases. Breast Can Res Treat. 2003;78:141–148. - PubMed
    1. Chang SC, Chang CC, Chang TJ, Wong ML. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998–2002) J Am Vet Med Assoc. 2005;227:1625–1629. - PubMed

MeSH terms

LinkOut - more resources